Business
Amarantus Diagnostics and Avant Diagnostics to Form 3-Way Business Combination with Theranostics Health
Amarantus Diagnostics and Avant Diagnostics to Form 3-Way Business Combination with Theranostics Health.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus Diagnostics and Avant Diagnostics to Form 3-Way Business Combination with Theranostics Health\n\n\n\n\n\nAmarantus Diagnostics and Avant Diagnostics to Form 3-Way Business Combination with Theranostics Health\nPR Newswire\nSCOTTSDALE, Arizona, SAN FRANCISCO and GAITHERSBERG, Maryland, March 7, 2016\n\n\n\nSCOTTSDALE, Arizona, SAN FRANCISCO and GAITHERSBERG, Maryland, March 7, 2016 /PRNewswire/ --\n\n\nCompanies to consolidate shares into Avant Diagnostics (OTCQB:AVDX)  \n\nConference Call to be hosted on Monday March 7, 2015 at 4:30pm ET that will include CEOs of Amarantus, Avant and Theranostics, and Amarantus advisor Brian Harvey, MD PhD \n\nCombined Company to focus on Oncology and Neurology diagnostics with 3 proprietary diagnostic tests for ovarian cancer (OvaDx®), multiple sclerosis (MSPrecise®) and Alzheimer's disease (LymPro Test®)CLIA-enabling validation studies for OvaDx® MSPrecise® and LymPro Test® expected to initiate in 2016 to support product launch in 2017 \n\n\n\n\nRich pipeline of oncology and neurodegeneration diagnostic products \n\nTheranostics Health expects recorded ~$1.5M in Pharma Services Revenue in 2015 that is expected to increase \n\nCustomer lists includes 7 of top 10 Pharmaceutical Companies \n\nScientific focus is on becoming recognized leader in field of cell cycle biology \n\n\nAvant Diagnostics (OTCQB: AVDX), a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), today announced that the companies have jointly entered into a letter of intent for Avant to acquire Theranostics Health Incorporated (\"THI\"), adding key CLIA laboratory and intellectual property capabilities to Avant and Amarantus' previously announced diagnostics merger. Theranostics currently generates over $1.5M in services revenue from some of the world's leading biopharmaceutical companies, including 7 of the top 10 pharmaceutical companies by revenue. To access today's 4:30pm ET conference call please dial 215-383-1625 or toll free 800-356-8278; access code 135394.\n\nUnder the terms of the agreement, Avant shall issue to Theranostics 25 million shares of its common stock upon the closing. Amarantus has provided a ...